Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: A placebo-controlled, randomized trial

Circulation

Volumn 96, Issue 1, 1997, Pages 183-191

  Basu, Sumit ^a   Senior, Roxy ^a   Raval, Usha ^a   Van Der Does, Reinhard ^a   Bruckner, Thomas ^a   Lahiri, Avijit ^a  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

Adrenergic beta antagonist; Myocardial infarction; Thrombolysis; Vasodilation

Indexed keywords

CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0030835669     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.1.183     Document Type: Article

References (41)

1. Yusuf S, Peto R, Lewis J, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis. 1985;17:335-371.
2. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI): a randomized placebo controlled international trial. Eur Heart J. 1985;6:199-226.
3. ISIS-I (First International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-I. Lancet. 1986; 2:57-66.
4. Norwegian Multicenter Study Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
5. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: mortality results. JAMA. 1982;247:1707-1714.
6. Roberts R, Rogers WJ, Mucller HS, Lambrew CT, Diver DJ, Smith HC, Willerson JT, Knatterud GL, Forman S, Passamani E, Zaret BL, Wackers FJT, Braunwald E, TIMI Investigators. Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) II-B study. Circulation. 1991;83:422-437.
7. Brener SJ, Cox JL, Pfisterer ME, Armstrong PW, Califf RM, Topol EJ, GUSTO Investigators. The potential for unexpected hazard of intravenous beta-blockade for acute myocardial infarction: results from the GUSTO trial. J Am Coll Cardiol. 1995;(suppl 5A):901-903.
8. Sponer G, Bartsch W, Strein K, Muller-Beckman B, Boehm E. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol. 1987;9:317-327.
9. Rodrigues EA, Lahiri A, Hughes LO, Kholi RS, Whittington JR, Raftery EB. Anti-anginal efficacy of carvedilol, a new beta-blocking drug with vasodilating activity. Am J Cardiol. 1986;58:916-921.
10. Heber ME, Brigden GS, Caruana MP, Lahiri A, Raftery EB. Carvedilol for systemic hypertension. Am J Cardiol. 1987;59: 400-405.
11. DasGupta P, Broadhurst P, Raftery EB, Lahiri A. Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1990;66:1118-1123.
12. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomised study. J Am Coll Cardiol. 1995;25:1225-1231.
13. Lahiri A, Rodrigues EA, Al-Khawaja I, Raftery EB. Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris. Am J Cardiol. 1987;59:769-774.
14. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
15. Hauf-Zachariou U, Widmann L, Zuelsdorf B, Hennig M, Lang PD. A double blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol. 1993;45:95-100.
16. Nakamoto H, Suzuki H, Katsumata H, Ohishi A, Saruta T, Sakaguchi H. Effects of carvedilol on renal function and blood pressure in three-fifth nephrectomized spontaneously hypertensive rats loaded with high salt. Drugs. 1988;336(suppl 6):160-164.
17. Ruffolo RR Jr, Boyle DA, Brooks DP, Feuerstein GZ, Venuti RP, Lukas MA, Poste G. Carvedilol: a novel cardiovascular drug with multiple actions. Cardiovasc Drugs Rev. 1992;10:127-157.
18. Kramer JH, Weglicki WB. A hydroxylated analog of the β-adrenoceptor antagonist, carvedilol, affords exceptional anti-oxidant protection to postischemic rat hearts. Free Radic Biol Med. 1996;21:813-825.
19. Gruppo Italiano per lo Studio della Streptochinasi nell'infarto Miocardico. Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet. 1987; 2:871-875.
20. Second International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS 2. Lancet. 1988;2:349-360.
21. Simoons ML, Vos J, Tijssen JGP, Vermeer F, Verheugt FWA, Krauss XH, Cats VM. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Inter University Cardiology Institute of the Netherlands. J Am Coll Cardiol. 1989;14:1609-1615.
22. DasGupta P, Broadhurst P, Lahiri A. The effects of intravenous carvedilol, a new multiple action vasodilatory β-blocker in congestive heart failure. J Cardiovasc Pharmacol. 1991;18(suppl 4):S12-S16.
23. Senior R, Buchner-Moell D, Raftery EB, Lahiri A. Potent hemodynamic effects of Bimakalim, a new potassium channel opener, in humans. J Cardiovasc Pharmacol. 1993;22:717-721.
24. Senior R, Sridhara BS, Basu S, Henley M, Handler CE, Raftery EB, Lahiri A. Comparison of radionuclide ventriculography and 2D echocardiography for the measurement of left ventricular ejection fraction following acute myocardial infarction. Eur Heart J. 1994; 15:1235-1239.
25. Buck JD, Hardman HF, Warltier DC, Gross GJ. Changes in ischemic blood flow distribution and dynamic severity of coronary stenoses induced by β-blockade in canine heart. Circulation. 1981;64: 708-715.
26. Yusuf S, Lopez R, Madison A, Sleight P. Variability of electrocardiographic and enzyme evolution of myocardial infarction in man. Br Heart J. 1981;45:271-280.
27. Yusuf S, Sleight P, Rosi PRF, Ramsdale D, Peto R, Furze L, Sterry H, Pearson M, Motwani R, Parish S, Gray R, Bennet D, Bray C. Reduction in infarct size, arrhythmias, chest pain, and morbidity by early intravenous β-blockade in suspected acute myocardial infarction. Circulation. 1983;67(suppl I):I-32-I-41.
28. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343: 1115-1122.
29. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet. 1993;342:821-828.
30. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342:1441-1446.
31. CIBIS Investigators and Committees. A randomised trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.
32. Lahiri A, Rodrigues EA, DasGupta P, Jain D, Van der Does R, Raftery EB. Effects of carvedilol in patients with impaired left ventricular function due to ischaemic heart disease. Z Kardiol. 1989;78(suppl 3):21-27.
33. Senior R, Glenville B, Basu S, Sridhara BS, Anagnostou E, Stanbridge R, Edmondson SJ, Handler CE, Raftery EB, Lahiri A. Dobutamine echocardiography and Tl-201 imaging predict functional improvement following revascularisation in severe ischaemic left ventricular dysfunction. Br Heart J. 1995;74:358-364.
34. Basu S, Sridhara B, Senior R, Duncker DM, Raval U, Handler CE, Raftery EB, Lahiri A. Role of thallium-201 reinjection in the assessment of myocardial viability following myocardial infarction. Br Heart J. 1993;69(suppl):61.
35. Lahiri A. Neurohumoral mechanisms in congestive heart failure and the role of drugs with multiple actions: a review of carvedilol. Am J Ther. 1996;3:237-247.
36. McKay RG, Pfeffer MA, Pasternak RC. Left ventricular remodeling following myocardial infarction: a corollary to infarct expansion. Circulation. 1986;74:693-702.
37. Marino P, Zanolla L, Zaerdini P. Effect of streptokinase on left ventricular modelling and function after myocardial infarction: the GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico) Trial. J Am Coll Cardiol. 1989;14: 1149-1158.
38. Vaughan D, Lamas G, Pfeffer MA. Role of left ventricular dysfunction in selective neurohormonal activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol. 1990;66:529-532.
39. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Circulation. 1990;81:1161-1172.
40. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669-677.
41. Ruffolo RR, Gellai M, Hieble JP, Willete RN, Nicholas AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38:82-88.